DOCSLIB.ORG

(Olaratumab Injection, 10 Mg/Ml), in • EMD Serono Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(Olaratumab Injection, 10 Mg/Ml), in • EMD Serono Inc tools Approved Drugs appropriate and which is not amenable review relates to avelumab’s proposed use in to curative treatment with radiotherapy patients with metastatic Merkel cell • Genentech (gene.com) announced that or surgery. carcinoma, based on tumor response results the U.S. Food and Drug Administration (FDA) from the JAVELIN Merkel 200 trial. has approved Avastin® (bevacizumab), • The FDA has granted accelerated approval either in combination with carboplatin and to Clovis Oncology’s (clovisoncology.com) • The FDA has accepted for review the new paclitaxel or in combination with carboplatin Rubraca® (rucaparib) for women with drug application (NDA) for ARIAD and gemcitabine chemotherapy, followed advanced ovarian cancer who have been Pharmaceuticals’ (ariad.com) investigational by Avastin alone, for the treatment of treated with two or more chemotherapies oral anaplastic lymphoma kinase (ALK) patients with platinum-sensitive recurrent and whose tumors have a specific inhibitor, brigatinib, in patients with epithelial ovarian, fallopian tube, or primary gene mutation (deleterious BRCA) as metastatic ALK-positive (ALK+) NSCLC who peritoneal cancer. identified by an FDA-approved companion have progressed on crizotinib. diagnostic test. • The FDA has approved Janssen Biotech’s • Arog Pharmaceuticals, Inc. (arogpharma. (janssen.com) Darzalex® (daratumumab) • Genentech (gene.com) announced com) announced that the FDA has granted in combination with lenalidomide and that the FDA has approved Tecentriq® fast track designation for crenolanib for the dexamethasone, or bortezomib and (atezolizumab) for the treatment of people treatment of patients with unresectable or dexamethasone, for the treatment of with metastatic NSCLC who have disease metastatic gastrointestinal stromal tumors patients with multiple myeloma who have progression during or following platinum- (GIST) harboring a platelet-derived growth received at least one prior therapy. containing chemotherapy, and have factor receptor alpha (PDGFRα) D842V progressed on an appropriate FDA-approved mutation. • Merck & Co., Inc. (merck.com) announced targeted therapy if their tumor has EGFR or that the FDA has approved Keytruda® ALK gene abnormalities. • The FDA has granted fast track designation (pembrolizumab) for the treatment of to Daiichi Sankyo Company’s (daiichisankyo. patients with metastatic non-small cell lung com) investigational HER2-targeting cancer (NSCLC) whose tumors express PD-L1 Drugs in the News antibody drug conjugate, DS-8201, for the as determined by an FDA-approved test. treatment of HER2-positive unresectable This approval also expands the indication in • The FDA has granted orphan drug and/or metastatic breast cancer in patients second-line treatment of lung cancer to designation to Ability Pharmaceuticals’ who have progressed after prior treatment include all patients with PD-L1-expressing (abilitypharma.com) ABTL0812 for the with HER2-targeted therapies including NSCLC. treatment of pancreatic cancer. ABTL0812 ado-trastuzumab emtansine (T-DM1). is an oral targeted anticancer compound • The FDA has approved Eli Lilly and that inhibits the PI3K/Akt/mTOR pathway. • Pfizer Inc. (pfizer.com) announced that Company’s (lillyoncology.com) Lartruvo™ the FDA has accepted for review a (olaratumab injection, 10 mg/mL), in • EMD Serono Inc. (emdserono.com) supplemental NDA for its CDK 4/6 inhibitor, combination with doxorubicin, for the announced that the FDA has accepted for Ibrance® (palbociclib). The supplemental treatment of adults with soft tissue sarcoma priority review the biologics license NDA supports the conversion of the acceler- with a histologic subtype for which an application (BLA) for the anti-PD-L1 IgG1 ated approval of Ibrance in combination anthracycline-containing regimen is monoclonal antibody avelumab. This 14 accc-cancer.org | January–February 2017 | OI with letrozole to regular approval and • Novartis (novartis.com) announced that restore the structure and function of the includes data from the Phase III PALOMA-2 the FDA has granted priority review to the esophagus subsequent to esophageal trial, which evaluated Ibrance as initial NDA for PKC412 (midostaurin) for the damage due to cancer, injury, or congenital therapy in combination with letrozole for treatment of acute myeloid leukemia in abnormalities. postmenopausal women with estrogen newly-diagnosed adults with an FMS-like receptor-positive, human epidermal growth tyrosine kinase-3 (FLT3) mutation, as well as factor receptor 2-negative (ER+, HER2-) for the treatment of advanced systemic Approved Genetic Tests & metastatic breast cancer. mastocytosis. Assays • Merck (merck.com) announced that the • Bayer (bayer.us) has submitted a • Roche (roche.com) announced FDA FDA accepted for review the supplemental supplemental NDA to the FDA for Stivarga® approval of the Ventana ALK (D5F3) CDx biologics license application (BLA) for (regorafenib) tablets for the second-line Assay for use on the Ventana BenchMark Keytruda® (pembrolizumab) for the systemic treatment of patients with ULTRA automated slide stainer. The assay is treatment of previously treated patients unresectable hepatocellular carcinoma. a companion diagnostic to aid in the with advanced microsatellite instability- identification of ALK-positive lung cancer high cancer. • The FDA has granted orphan drug patients who are eligible for treatment with designation to AbbVie’s (abbvieoncology. Pfizer’s FDA-approved therapy Xalkori® • The FDA has granted priority review to com) veliparib, an oral PARP inhibitor, being (crizotinib). LEE011 (ribociclib) (Novartis, novartis.com) investigated in combination with chemo- The FDA has also approved Roche’s as first-line treatment of postmenopausal therapies, such as carboplatin and pacli- Ventana PD-L1 (SP142) Assay as a women with hormone-receptor positive, taxel, or radiation for the treatment of complementary diagnostic to identify PD-L1 human epidermal growth factor receptor-2 advanced NSCLC. expression levels in patients considering negative (HR+/HER2-) advanced or metastatic treatment with the FDA-approved Roche breast cancer in combination with letrozole. • Astellas Pharma Inc. (astellas.com/en) cancer immunotherapy Tecentriq® and Pfizer Inc. (pfizer.com) announced that (atezolizumab) for previously treated • Mylan (mylan.com) and Biocon Ltd. the FDA has approved a supplemental NDA metastatic NSCLC. The PD-L1 (SP142) assay is (biocon.com) announced submission of to update the U.S. product labeling for also indicated to identify patients with Mylan’s BLA for MYL-1401O, a proposed Xtandi® (enzalutamide) capsules to urothelial cancer who may benefit from biosimilar to trastuzumab, which is include new clinical data versus bicalut- treatment with Tecentriq. indicated to treat certain HER2-positive amide from the TERRAIN study. The data breast and gastric cancers. demonstrate improvement in radiographic progression-free survival in patients with • The FDA has granted orphan drug metastatic castration-resistant prostate Label Change designation to Boston Biomedical’s cancer who were treated with enzalutamide for Tarceva® (bostonbiomedical.com) lead investigational compared to patients who were treated The FDA modified the indication for compound, napabucasin, for the treatment with bicalutamide. Tarceva (erlotinib) (Astellas Pharm of pancreatic cancer. Global Development Inc., astellas. com/en) for treatment of NSCLC to • Boehringer Ingelheim (boehringer- Approved Devices limit use to patients whose tumors ingelheim.us) announced that the FDA has have specific EGFR mutations. The granted orphan drug designation to • Exact Imaging (exactimaging.com) has labeling change applies to patients nintedanib for the treatment of received FDA 510(k) clearance for its with NSCLC receiving maintenance mesothelioma. ExactVu™ micro-ultrasound system, or second or greater line treatment. which performs targeted prostate biopsies. These indications will be limited to • The FDA has granted priority review for those patients whose tumors have Tesaro, Inc.’s (tesarobio.com) NDA for • The FDA had approved ZDi Solutions’ EGFR exon 19 deletions or exon 21 Niraparib. Niraparib, formerly known as (zdirad.com) Z-System™ patient positioning L858R substitution mutations as MK-4827, is an orally active and potent poly device for proton therapy and conventional detected by an FDA-approved test. (ADP-ribose) polymerase, or PARP, inhibitor radiation therapy. The system is comprised The first-line indication previously that is being evaluated as a potential new of the Z-Box™, Z-Square™, and Z-Tilt™. was limited to patients with treatment option for patients with recurrent EGFR exon 19 deletions or exon 21 epithelial ovarian, fallopian tube, or primary • Biostage, Inc. (biostage.com) announced substitution mutations. peritoneal cancer following response to that its Cellspan™ Esophageal Implant was platinum-based chemotherapy. granted FDA orphan drug designation to OI | January–February 2017 | accc-cancer.org 15.
Load more

Recommended publications
  • Pertuzumab and Trastuzumab: the Rationale Way to Synergy
    Anais da Academia Brasileira de Ciências (2016) 88(1 Suppl.): 565-577 (Annals of the Brazilian Academy of Sciences) Printed version ISSN 0001-3765 / Online version ISSN 1678-2690 http://dx.doi.org/10.1590/0001-3765201620150178 www.scielo.br/aabc Pertuzumab and trastuzumab: the rationale way to synergy SANDRINE RICHARD1, FRÉDÉRIC SELLE1, JEAN-PIERRE LOTZ1,2, AHMED KHALIL1, JOSEPH GLIGOROV1,2 and DANIELE G. SOARES1 1Medical Oncology Department, APREC (Alliance Pour la Recherche En Cancérologie), Tenon Hospital (Hôpitaux Universitaires de l’Est-Parisien, AP-HP), rue de la Chine, 75020 Paris, France 2Institut Universitaire de Cancérologie Université Pierre et Marie Curie (IUC-UPMC Univ Paris 06), Sorbonne Universités, 4 place Jussieu, 75005 Paris, France Manuscript received on March 13, 2015; accepted for publication on May 5, 2015 ABSTRACT It has now been 15 years since the HER2-targeted monoclonal antibody trastuzumab was introduced in clinical and revolutionized the treatment of HER2-positive breast cancer patients. Despite this achievement, most patients with HER2-positive metastatic breast cancer still show progression of their disease, highlighting the need for new therapies. The continuous interest in novel targeted agents led to the development of pertuzumab, the first in a new class of agents, the HER dimerization inhibitors. Pertuzumab is a novel recombinant humanized antibody directed against extracellular domain II of HER2 protein that is required for the heterodimerization of HER2 with other HER receptors, leading to the activation of downstream signalling pathways. Pertuzumab combined with trastuzumab plus docetaxel was approved for the first-line treatment of patients with HER2-positive metastatic breast cancer and is currently used as a standard of care in this indication.
    [Show full text]
  • Trastuzumab, Biosimilars, Trastuzumab-Hyaluronidase
    Clinical Policy: Trastuzumab, Biosimilars, Trastuzumab-Hyaluronidase Reference Number: CP.PHAR.228 Effective Date: 06.01.16 Last Review Date: 05.20 Coding Implications Line of Business: Commercial, HIM, Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory and legal information. Description Trastuzumab (Herceptin®) is a human epidermal growth factor receptor 2 (HER2)/neu receptor antagonist. Trastuzumab-dkst (Ogivri™), trastuzumab-pkrb (Herzuma®), trastuzumab-dttb (Ontruzant®), trastuzumab-qyyp (Trazimera™), and trastuzumab-anns (Kanjinti™) are Herceptin biosimilars. Trastuzumab-hyaluronidase-oysk (Herceptin Hylecta™) is a combination of trastuzumab and hyaluronidase, an endoglycosidase. FDA Approved Indication(s) Indications* Description Herceptin, Herzuma Herceptin Ogivri, Hylecta Ontruzant, Trazimera, Kanjinti Adjuvant For adjuvant As part of a treatment X X X breast cancer treatment of regimen consisting of HER2- doxorubicin, overexpressing cyclophosphamide, node positive and either paclitaxel or node or docetaxel negative As part of a treatment X X X (ER/PR regimen with negative or docetaxel and with one high carboplatin risk feature) As a single agent X X X breast cancer: following multi- modality anthracycline based therapy Metastatic In combination with paclitaxel for first- X X X breast cancer line treatment of HER2-overexpressing metastatic breast cancer As a single agent for treatment of X X X HER2-overexpressing breast cancer in patients who have received one or more Page 1 of 13
    [Show full text]
  • Cancer Drug Pharmacology Table
    CANCER DRUG PHARMACOLOGY TABLE Cytotoxic Chemotherapy Drugs are classified according to the BC Cancer Drug Manual Monographs, unless otherwise specified (see asterisks). Subclassifications are in brackets where applicable. Alkylating Agents have reactive groups (usually alkyl) that attach to Antimetabolites are structural analogues of naturally occurring molecules DNA or RNA, leading to interruption in synthesis of DNA, RNA, or required for DNA and RNA synthesis. When substituted for the natural body proteins. substances, they disrupt DNA and RNA synthesis. bendamustine (nitrogen mustard) azacitidine (pyrimidine analogue) busulfan (alkyl sulfonate) capecitabine (pyrimidine analogue) carboplatin (platinum) cladribine (adenosine analogue) carmustine (nitrosurea) cytarabine (pyrimidine analogue) chlorambucil (nitrogen mustard) fludarabine (purine analogue) cisplatin (platinum) fluorouracil (pyrimidine analogue) cyclophosphamide (nitrogen mustard) gemcitabine (pyrimidine analogue) dacarbazine (triazine) mercaptopurine (purine analogue) estramustine (nitrogen mustard with 17-beta-estradiol) methotrexate (folate analogue) hydroxyurea pralatrexate (folate analogue) ifosfamide (nitrogen mustard) pemetrexed (folate analogue) lomustine (nitrosurea) pentostatin (purine analogue) mechlorethamine (nitrogen mustard) raltitrexed (folate analogue) melphalan (nitrogen mustard) thioguanine (purine analogue) oxaliplatin (platinum) trifluridine-tipiracil (pyrimidine analogue/thymidine phosphorylase procarbazine (triazine) inhibitor)
    [Show full text]
  • Federal Register Notice 5-1-2020 Pdf Icon[PDF – 358
    Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices 25439 confidential by the respondent (5 U.S.C. schedules. Other than examination DEPARTMENT OF HEALTH AND 552(b)(4)). reports, it provides the only financial HUMAN SERVICES Current actions: The Board has data available for these corporations. temporarily revised the instructions to The Federal Reserve is solely Centers for Disease Control and the FR Y–9C report to accurately reflect responsible for authorizing, supervising, Prevention the revised definition of ‘‘savings and assigning ratings to Edges. The [CDC–2020–0046; NIOSH–233–C] deposits’’ in accordance with the Federal Reserve uses the data collected amendments to Regulation D in the on the FR 2886b to identify present and Hazardous Drugs: Draft NIOSH List of interim final rule published on April 28, potential problems and monitor and Hazardous Drugs in Healthcare 2020 (85 FR 23445). Specifically, the develop a better understanding of Settings, 2020; Procedures; and Risk Board has temporarily revised the activities within the industry. Management Information instructions on the FR Y–9C, Schedule HC–E, items 1(b), 1(c), 2(c) and glossary Legal authorization and AGENCY: Centers for Disease Control and content to remove the transfer or confidentiality: Sections 25 and 25A of Prevention, HHS. withdrawal limit. As a result of the the Federal Reserve Act authorize the ACTION: Notice and request for comment. revision, if a depository institution Federal Reserve to collect the FR 2886b chooses to suspend enforcement of the (12 U.S.C. 602, 625). The obligation to SUMMARY: The National Institute for six transfer limit on a ‘‘savings deposit,’’ report this information is mandatory.
    [Show full text]
  • Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy
    cancers Review Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy Laura Boyero 1 , Amparo Sánchez-Gastaldo 2, Miriam Alonso 2, 1 1,2,3, , 1,2, , José Francisco Noguera-Uclés , Sonia Molina-Pinelo * y and Reyes Bernabé-Caro * y 1 Institute of Biomedicine of Seville (IBiS) (HUVR, CSIC, Universidad de Sevilla), 41013 Seville, Spain; [email protected] (L.B.); [email protected] (J.F.N.-U.) 2 Medical Oncology Department, Hospital Universitario Virgen del Rocio, 41013 Seville, Spain; [email protected] (A.S.-G.); [email protected] (M.A.) 3 Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain * Correspondence: [email protected] (S.M.-P.); [email protected] (R.B.-C.) These authors contributed equally to this work. y Received: 16 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Immuno-oncology has redefined the treatment of lung cancer, with the ultimate goal being the reactivation of the anti-tumor immune response. This has led to the development of several therapeutic strategies focused in this direction. However, a high percentage of lung cancer patients do not respond to these therapies or their responses are transient. Here, we summarized the impact of immunotherapy on lung cancer patients in the latest clinical trials conducted on this disease. As well as the mechanisms of primary and acquired resistance to immunotherapy in this disease. Abstract: After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field.
    [Show full text]
  • Trastuzumab Products
    1 Trastuzumab Products: Trastuzumab (Herceptin®), Trastuzumab-anns (Kanjinti®), Trastuzumab-dkst (Ogivri®), Trastuzumab-dttb (Ontruzant®), Trastuzumab-pkrb (Herzuma®), Trastuzumab-qyyp (Trazimera®) Prior Authorization Drug Coverage Policy Effective Date: 11/9/2020 Revision Date: n/a Review Date: 10/27/2020 Lines of Business: Commercial Policy type: Prior Authorization This Drug Coverage Policy provides parameters for the coverage of trastuzumab products, which includes Trastuzumab (Herceptin®), Trastuzumab-anns (Kanjinti ®), Trastuzumab-dkst (Ogivri ®), Trastuzumab-dttb (Ontruzant®), Trastuzumab-pakrb (Herzuma®), and Trastuzumab-qyyp (Trazimera ®). Consideration of medically necessary indications are based upon U.S. Food and Drug Administration (FDA) indications, recommended uses within the Centers of Medicare & Medicaid Services (CMS) five recognized compendia, including the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium (NCCN Category 1 or 2A recommendations), and peer-reviewed scientific literature eligible for coverage according to the CMS, Medicare Benefit Policy Manual, Chapter 15, section 50.4.5 titled, “Off-Label Use of Anti- Cancer Drugs and Biologics.” This policy evaluates whether the drug therapy is proven to be effective based on published evidence-based medicine. Drug Description 1 The human epidermal growth factor receptor 2 (HER2) proto-oncogene encodes a transmembrane receptor protein of 185 kDa, which is structurally related to the epidermal growth factor receptor. Trastuzumab products have been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumor cells that overexpress HER2. Trastuzumab products are mediators of antibody-dependent cellular cytotoxicity (ADCC). In vitro , trastuzumab product mediated ADCC has been shown to be preferentially exerted on HER2 overexpressing cancer cells compared with cancer cells that do not overexpress HER2.
    [Show full text]
  • HIV MARKET REPORT the State of HIV Treatment, Testing, and Prevention in Low- and Middle-Income Countries
    HIV MARKET REPORT The state of HIV treatment, testing, and prevention in low- and middle-income countries Issue 10, September 2019 Test Treat Stay Smart Right Negative This report was made possible through the generous support of Unitaid, with complementary support from the UK Department for International Development (DFID) and the Bill & Melinda Gates Foundation. Table of Contents Acronyms Used .................................................................................................................................................................... 4 Foreword .............................................................................................................................................................................. 5 2019 Market Report At-a-Glance ..................................................................................................................................... 6 GENERAL TRENDS ........................................................................................................................................................... 7 Figure 1: Major HIV Pricing Updates as of Sep. 2019 .......................................................................................................................... 7 Figure 2: Generic-accessible (GA) LMIC Weighted Average Regimen Price (USD, PPPY) .................................................... 7 Figure 3: HIV Resources in LMICs, 2000-2018 .....................................................................................................................................
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response
    cancers Article ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response Femke A. I. Ehlers 1,2,3 , Nicky A. Beelen 1,2,3, Michel van Gelder 2,3, Tom M. J. Evers 1,3,4, Marjolein L. Smidt 3,5, Loes F. S. Kooreman 3,6 , Gerard M. J. Bos 2,3 and Lotte Wieten 1,3,* 1 Department of Transplantation Immunology, Tissue Typing Laboratory, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands; [email protected] (F.A.I.E.); [email protected] (N.A.B.); [email protected] (T.M.J.E.) 2 Department of Internal Medicine, Division of Hematology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands; [email protected] (M.v.G.); [email protected] (G.M.J.B.) 3 GROW—School for Oncology and Developmental Biology, Maastricht University, 6229 GT Maastricht, The Netherlands; [email protected] (M.L.S.); [email protected] (L.F.S.K.) 4 Medical Systems Biophysics and Bioengineering, Leiden Academic Centre for Drug Research, Faculty of Science, Leiden University, 2333 CC Leiden, The Netherlands 5 Department of Surgery, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands 6 Department of Pathology, Maastricht University Medical Center+, 6229 HX Maastricht, The Netherlands * Correspondence: [email protected] Citation: Ehlers, F.A.I.; Beelen, N.A.; Simple Summary: Natural killer (NK) cells are potent killers of tumor cells. Many tumors, includ- van Gelder, M.; Evers, T.M.J.; Smidt, ing breast cancers, develop mechanisms to suppress anti-tumor immune responses, requiring the M.L.; Kooreman, L.F.S.; Bos, G.M.J.; development of strategies to overcome suppression.
    [Show full text]
  • CDER Breakthrough Therapy Designation Approvals Data As of December 31, 2020 Total of 190 Approvals
    CDER Breakthrough Therapy Designation Approvals Data as of December 31, 2020 Total of 190 Approvals Submission Application Type and Proprietary Approval Use Number Number Name Established Name Applicant Date Treatment of patients with previously BLA 125486 ORIGINAL-1 GAZYVA OBINUTUZUMAB GENENTECH INC 01-Nov-2013 untreated chronic lymphocytic leukemia in combination with chlorambucil Treatment of patients with mantle cell NDA 205552 ORIGINAL-1 IMBRUVICA IBRUTINIB PHARMACYCLICS LLC 13-Nov-2013 lymphoma (MCL) Treatment of chronic hepatitis C NDA 204671 ORIGINAL-1 SOVALDI SOFOSBUVIR GILEAD SCIENCES INC 06-Dec-2013 infection Treatment of cystic fibrosis patients age VERTEX PHARMACEUTICALS NDA 203188 SUPPLEMENT-4 KALYDECO IVACAFTOR 21-Feb-2014 6 years and older who have mutations INC in the CFTR gene Treatment of previously untreated NOVARTIS patients with chronic lymphocytic BLA 125326 SUPPLEMENT-60 ARZERRA OFATUMUMAB PHARMACEUTICALS 17-Apr-2014 leukemia (CLL) for whom fludarabine- CORPORATION based therapy is considered inappropriate Treatment of patients with anaplastic NOVARTIS lymphoma kinase (ALK)-positive NDA 205755 ORIGINAL-1 ZYKADIA CERITINIB 29-Apr-2014 PHARMACEUTICALS CORP metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib Treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients NDA 206545 ORIGINAL-1 ZYDELIG IDELALISIB GILEAD SCIENCES INC 23-Jul-2014 for whom rituximab alone would be considered appropriate therapy due to other co-morbidities
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma
    Genmab Announces European Marketing Authorization for DARZALEX® (Daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone in Frontline Multiple Myeloma Company Announcement DARZALEX® (daratumumab) approved in Europe in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant Approval follows positive opinion by European Committee for Medicinal Products for Human Use (CHMP) in December Approval based on data from Phase III CASSIOPEIA study Copenhagen, Denmark; January 20, 2020 – Genmab A/S (Nasdaq: GMAB) announced today that the European Commission (EC) has granted marketing authorization for DARZALEX® (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant (ASCT). The EC approval follows a positive opinion issued for DARZALEX by the CHMP of the European Medicines Agency (EMA) in December 2019. In August 2012, Genmab granted Janssen Biotech, Inc. (Janssen) an exclusive worldwide license to develop, manufacture and commercialize daratumumab. “With this approval, newly diagnosed patients with multiple myeloma who are eligible for ASCT may have the opportunity for treatment with a DARZALEX-containing regimen. We are extremely pleased that DARZALEX has received this latest approval and we look forward to the combination of DARZALEX plus bortezomib, thalidomide and dexamethasone being launched in Europe,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. The approval was based on the Phase III CASSIOPEIA (MMY3006) study sponsored by the French Intergroupe Francophone du Myelome (IFM) in collaboration with the Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen R&D, LLC.
    [Show full text]